Repligen Corporation reported publication of research that identifies histone deacetylase 3 as an important enzyme target for therapeutic intervention in neurodegenerative disease. These research findings confirm the drug target of the HDAC inhibitors that Repligen is currently developing for the treatment of inherited neurodegenerative diseases. The study, entitled “Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich’s Ataxia Gene Silencing” published in the journal Chemistry & Biology (volume 16, 980-989, September 25, 2009), was conducted in collaboration with scientists at The Scripps Research Institute. Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.
Click here to read more.Share this: